• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

20.09 -2.38 (-10.57%)
Streaming Delayed Price Updated: 1:36 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,944,378
Open 22.53
Bid (Size) 20.06 (300)
Ask (Size) 20.13 (200)
Prev. Close 22.47
Today's Range 19.93 - 22.58
52wk Range 10.57 - 23.77
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Today 10:07 EDT
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 25, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+23.5%
+23.5%
1 Month
-3.7%
-3.7%
3 Month
+18.3%
+18.3%
6 Month
+49.1%
+49.1%
1 Year
+42.3%
+42.3%

More News

Read More
News headline image
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 05, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
February 02, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
January 29, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 06, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 30, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗
December 10, 2025
Via The Motley Fool
News headline image
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Board and Executive Leadership Updates
November 06, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate ↗
October 14, 2025
Via Benzinga
News headline image
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 13, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 11, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 07, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 06, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
What Happened To Denali Therapeutics Stock Wednesday? ↗
April 02, 2025
Via Benzinga
News headline image
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 02, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Denali Therapeutics Inc. - Common Stock publicly traded?
Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Denali Therapeutics Inc. - Common Stock trade on?
Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 20.09
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 03/26/26 01:36 PM ET
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 2.44B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap